Conflict of interest statement: Competing interests: ML served as a consultantfor Teva and received a travel grant from Astellas outside the submitted work.EdA received honoraria from Roche-Genentech, research grant from Roche–Genentech (to the insitution) and travel grants from Roche-Genentech and GlaxoSmithKlineoutside the submitted work. GV has no conflicts of interest to declare.192. Clin Case Rep. 2018 Feb 16;6(4):634-637. doi: 10.1002/ccr3.1382. eCollection 2018Apr.Frontline brentuximab vedotin in breast implant-associated anaplastic large-cell lymphoma.Alderuccio JP(1), Desai A(1), Yepes MM(2), Chapman JR(3), Vega F(3), LossosIS(1)(4).Author information: (1)Division of HematologyDepartment of MedicineSylvester Comprehensive CancerCenterUniversity of Miami Miller School of MedicineMiamiFLUSA.(2)Department of RadiologySylvester Comprehensive Cancer CenterUniversity ofMiami Miller School of MedicineMiamiFLUSA.(3)Division of HematopathologyDepartment of Pathology and LaboratoryMedicineSylvester Comprehensive Cancer CenterUniversity of Miami Miller School ofMedicineMiamiFLUSA.(4)Department of Molecular and Cellular PharmacologySylvester ComprehensiveCancer CenterUniversity of Miami Miller School of MedicineMiamiFLUSA.We report a woman who developed BIA-ALCL 9 years after saline implant placement. The lymphoma manifested as a mass lesion associated with axillarylymphadenopathy. She was successfully treated with brentuximab vedotin withminimal toxicity. Brentuximab vedotin may be a promising frontline therapeuticmodality for patients with BIA-ALCL.DOI: 10.1002/ccr3.1382 PMCID: PMC5889253PMID: 29636930 